Skip to main content
Equibles

J. Goldman & Co LP

Position in URGN — UroGen Pharma Ltd.

CIK 1412741 NEW YORK, NY
Back to URGN Full portfolio

Position in URGN

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$7,830,120
-$9,050,762 QoQ
Shares Held
212,775
-77.3% QoQ
Ownership
0.435%
of shares outstanding
% of Portfolio
0.29%
of 13F equity value
Holder Rank
#31
of 190 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in URGN Over Time

Shares Held

Position Value (USD)

Derivatives in URGN

reported options exposure · as of Jun 30, 2026
CallValue
$1,251,200
CallShares
34,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

J. Goldman & Co LP holds $154,729,761 across 52 Biotechnology names. URGN ranks #6 (5.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 COGT
Cogent Biosciences, Inc.
 637,994 $24,690,367
2 ALNY
Alnylam Pharmaceuticals, Inc.
 38,698 $11,649,258
3 CAPR
Capricor Therapeutics, Inc.
 427,321 $10,289,889
4 MGTX
MeiraGTx Holdings plc
 601,972 $8,132,641
5 ARDX
Ardelyx, Inc.
 1,579,828 $8,057,122
6 URGN
UroGen Pharma Ltd.
This page 		212,775 $7,830,120
7 VRTX
Vertex Pharmaceuticals Inc / Ma
 12,311 $6,115,243
8 ELVN
Enliven Therapeutics, Inc.
 112,129 $5,690,546

All Filings in URGN

Export CSV
6 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $7,830,120 212,775
2026-06-30 $1,251,200 34,000
2026-03-31 $16,880,882 938,870
2026-03-31 $899,000 50,000
2025-12-31 $1,967,280 84,000
2025-12-31 $12,021,556 513,303